HLA implementation study – The use of an HLA risk allele panel test to identify people vulnerable to drug hypersensitivity
Recruiting
- Conditions
- Drug hypersensitivity
- Registration Number
- NL-OMON21376
- Lead Sponsor
- not applicable
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 500
Inclusion Criteria
•At least 18 years of age
•Eligible for a medication verification interview at the LUMC
•Can give informed consent
•Able to give saliva
•Suitable to participate in the opinion of the researcher.
Exclusion Criteria
•Pregnant or lactating;
•Has already been tested for HLA in the past (e.g. organ donors and recipients)
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method the mean number of HLA risk alleles.
- Secondary Outcome Measures
Name Time Method not applicable